Genedata Introduces AI Analytics to Enhance Quality Control and Novel Phenotype Detection in High-Content Screening
Summary
Genedata Imagence now also automatically flags novel phenotypes (e.g. reflecting new, hitherto undiscovered modes of drug action), thus enabling scientists to focus their attention on new hypotheses generated by such a priori unexpected results. In combination with its innovative visualizations, Genedata Imagence 3.0 thus enables very rapid incorporation of new findings into already trained neural network models and the efficient (re-)analysis of other and larger high content screens. The software is designed to integrate easily with other enterprise software systems, offering full data capture options and image store integration within a full, smooth analysis workflow for screening applications, from raw data to pharmacological endpoints. “It’s also proof of our focus on helping our customers to speed up their R&D processes, reducing costs due to poor data quality and enabling efficient collaboration within a highly challenging domain.” • New Genedata Imagence 3.0 will be presented at the SLAS2021 Digital International Conference and Exhibition on Tuesday, January 26, 2021; 1:30–2:00 pm EST. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
Classifications
AskAI Classifications
LabelsLinked Companies
